Literature DB >> 19966137

ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses.

Ville Pulkkinen1, Sara Bruce, Johanna Rintahaka, Ulla Hodgson, Tarja Laitinen, Harri Alenius, Vuokko L Kinnula, Marjukka Myllärniemi, Sampsa Matikainen, Juha Kere.   

Abstract

Viral infections and abnormal host response are thought to cause epithelial injury in idiopathic pulmonary fibrosis (IPF). To understand IPF pathogenesis, we have used overexpression cell models and expression microarrays to discover genes networked with ELMO domain containing 2 (ELMOD2) gene genetically implicated in IPF. The identified pathways were confirmed in vitro, and ELMOD2 protein expression was characterized in tissue samples. Here 303 genes were significantly altered after ELMOD2 transfection of human alveolar epithelial A549 cell line. The enriched pathways were interferon induction, viral response, antigen processing and presentation, and I-/nuclear factor-kappaB signaling. ELMOD2 showed immunoreactivity in macrophages and type II alveolar epithelial cells in normal human lung. In A549 cells, forced expression of ELMOD2 increased type I and type III interferon mRNA expression, and ELMOD2-specific siRNA molecules inhibited expression of these antiviral cytokines in response to Toll-like receptor three (TLR3) activation. In human macrophages silencing of ELMOD2 inhibited TLR3-dependent expression of type I and type III interferon genes. Influenza A virus infection decreased ELMOD2 mRNA expression in A549 cells and macrophages suggesting negative regulation in viral infections. In summary, our results show that TLR3 pathway is dependent on ELMOD2.-Pulkkinen, V., Bruce, S., Rintahaka, J., Hodgson, U., Laitinen, T., Alenius, H., Kinnula, V. L., Myllärniemi, M., Matikainen, S., Kere, J. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966137     DOI: 10.1096/fj.09-138545

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  The genetic basis of idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; Timothy S Blackwell; James E Loyd
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

3.  ELMO domains, evolutionary and functional characterization of a novel GTPase-activating protein (GAP) domain for Arf protein family GTPases.

Authors:  Michael P East; J Bradford Bowzard; Joel B Dacks; Richard A Kahn
Journal:  J Biol Chem       Date:  2012-09-26       Impact factor: 5.157

4.  Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

Authors:  Alvar Agustí; Josep Maria Antó; Charles Auffray; Ferran Barbé; Esther Barreiro; Jordi Dorca; Joan Escarrabill; Rosa Faner; Laura I Furlong; Judith Garcia-Aymerich; Joaquim Gea; Bertil Lindmark; Eduard Monsó; Vicente Plaza; Milo A Puhan; Josep Roca; Juan Ruiz-Manzano; Laura Sampietro-Colom; Ferran Sanz; Luis Serrano; James Sharpe; Oriol Sibila; Edwin K Silverman; Peter J Sterk; Jacob I Sznajder
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

Review 5.  TLR3 immunity to infection in mice and humans.

Authors:  Shen-Ying Zhang; Melina Herman; Michael J Ciancanelli; Rebeca Pérez de Diego; Vanessa Sancho-Shimizu; Laurent Abel; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2013-01-03       Impact factor: 7.486

Review 6.  Molecular biomarkers in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Kevin K Brown; Harold R Collard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-09-26       Impact factor: 5.464

Review 7.  Viral infection and aging as cofactors for the development of pulmonary fibrosis.

Authors:  Payal K Naik; Bethany B Moore
Journal:  Expert Rev Respir Med       Date:  2010-12       Impact factor: 3.772

8.  Telomere shortening activates TGF-β/Smads signaling in lungs and enhances both lipopolysaccharide and bleomycin-induced pulmonary fibrosis.

Authors:  Ying-Ying Liu; Yao Shi; Ya Liu; Xing-Hua Pan; Ke-Xiong Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-06-20       Impact factor: 6.150

9.  GTPase-activating protein Elmod2 is essential for meiotic progression in mouse oocytes.

Authors:  Chun-Xiang Zhou; Li-Ya Shi; Rui-Chao Li; Ya-Hong Liu; Bo-Qun Xu; Jin-Wei Liu; Bo Yuan; Zhi-Xia Yang; Xiao-Yan Ying; Dong Zhang
Journal:  Cell Cycle       Date:  2017-03-21       Impact factor: 4.534

Review 10.  Personalized medicine: applying 'omics' to lung fibrosis.

Authors:  Jose D Herazo-Maya; Naftali Kaminski
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.